Most analysts and doctors were expecting the FDA to seek additional information before approving Arcoxia because Merck pulled Vioxx from the market last month after a study showed it doubled patients risk of heart attacks and strokes.
Now there are concerns that the entire class of drugs cause similar problems The European Medicines Agency said its review will look at all aspects of cardiovascular safety of the Cox-2 drugs.
Many analysts and doctors believe Arcoxia will only be approved after that study is completed and it demonstrates the drug doesn't increase the risk of heart attacks and strokes The 7,111-patient
